Hydromer, Inc. has announced a strategic investment from JMEDTECH alongside significant changes to its board leadership structure. The partnership establishes what the companies describe as a future-oriented global medical device coating platform that integrates UV-curable and thermal-cure coating systems with advanced coating equipment and regionalized services. This strategic move aims to significantly enhance supply chain resilience and responsiveness while creating greater value for customers worldwide.
The collaboration connects capabilities across Asia and the Americas, establishing what the company calls a mirror-delivery network covering major medical device markets. The platform provides comprehensive solutions spanning research and development, validation, and mass production phases. CEO Michael Torti emphasized the significance of the partnership, stating that combining with JMEDTECH will bring perhaps the broadest range of coating capabilities to the global medical device marketplace. This includes automatic large-scale coating systems that represent significant advancement in coating technology delivery.
Michael Torti will continue to serve as CEO and Director, working with newly appointed Chairman Jacqueline Zhang and the restructured Board of Directors. The company expressed gratitude to departing directors Braeden Lichti and George Kovalyov for their leadership and contributions to the organization. The strategic investment and board restructuring come as Hydromer enters what company leadership describes as its next phase of growth and innovation.
Hydromer, founded in 1980, has operated as a leader in hydrophilic, thromboresistant, and antimicrobial coating technologies for medical devices for over 44 years. The company maintains ISO 9001:2015 certification and operates facilities compliant with Good Manufacturing Practice standards. The organization manages numerous global business-to-business services including proprietary coating formulations, custom coating services, research and development, analytical testing, and dedicated machinery building and support.
The partnership leverages Hydromer's four decades of experience in surface conversion coatings with JMEDTECH's innovative approach to medical device technology. Together, the companies aim to establish a dominant position in the markets they serve while enhancing value for shareholders, employees, and customers through expanded technological capabilities and global market access. The collaboration marks a critical milestone in JMEDTECH's global expansion strategy while amplifying Hydromer's technological and brand influence across international markets.
